The company's development strategy is to target the liver using a novel synthetic adeno associated virus (AAV-ANC80) to introduce therapeutic genes to hepatocytes, correcting the genetic disorder.

Vivet is collaborating with strategic partners to address various inherited disorders such as Wilson's disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and Citrullinemia type I. The company is working with the Center for Applied Medical Research (CIMA) in Pamplona, Spain.